Purpose: To determine the presenting characteristics of patients with neovascular agerelated macular degeneration with long-term remission (LTR), which was defined as the absence of intraretinal/subretinal fluid, or hemorrhage, and absence of leakage on fluorescein angiography for longer than 6 months while on as-needed antivascular endothelial growth factor treatment.
A ge-related macular degeneration (AMD) is the leading cause of visual impairment and blindness in industrialized countries. 1, 2 There have been significant advances in the management of neovascular-or wet AMD-with the introduction of antivascular endothelial growth factor (anti-VEGF) agents. The pivotal ANCHOR and MARINA clinical trials demonstrated superior visual acuity results with monthly ranibizumab injections compared with photodynamic therapy or observation. 3, 4 The Comparison of Age Related Macular Degeneration Treatment Trials (CATT) indicated that bevacizumab (Avastin; Genenetech, San Francisco, CA) had a similar treatment effect and safety profile compared with ranibizumab (Lucentis; Genentech, San Francisco, CA). 5 The VIEW 1 and VIEW 2 studies revealed that subjects in one arm exhibited similar visual outcomes when comparing aflibercept (Eylea; Regeneron Pharmaceuticals Inc, Tarrytown, NY) 2 mg dosed every 2 months after a 3-monthly loading dose to monthly ranibizumab 0.5 mg. 6 Although the 2-year results of CATT study demonstrated that pro re nata (PRN) regimen resulted in less gain of visual acuity than monthly injections, 7 PRN or treat-and-extend regimens are commonly used to reduce treatment burden for both patients and doctors. 8, 9 Reducing injection frequency might also reduce risk of arterial thromboembolic events, which are noted as potential side effects of anti-VEGF agents such as ranibizumab. 10 Another reason favoring less frequent dosing stems from animal model and clinical studies suggesting progression of geographic atrophy in response to sustained exposure to anti-VEGF agents. 11 The CATT study showed that in treated wet AMD eyes, monthly dosing was associated with more geographic atrophy than PRN dosing. 11 In animal studies, inhibition of retinal pigment epithelium (RPE)-derived VEGF-A and other isoforms may blunt neuroprotective and trophic effects on the choriocapillaris and photoreceptors, thereby leading to tissue loss. 12 Interestingly, it was reported in the CATT 5-year follow-up study that 96 patients (14.8%) received no treatments between the end of the 2-year clinical trial and the 5-year CATT follow-up study visit. Among these 96 patients, 21 of 43 patients (48.8%) in the PRN treatment arm received no treatment during Year 2 of the clinical trial. 13 In a recent retrospective study, Kuroda et al, 14 looked for the predictors of recurrence of wet AMD after a loading phase of 3 monthly ranibizumab injections and found that older age and male gender predicted earlier recurrence, and polypoidal choroidal vasculopathy was associated with a shorter interval to recurrence.
In our practice, most of PRN-treated AMD patients do not get long-term remission (LTR) ($6 months) after anti-VEGF injections, but we have observed that there is a small group of patients who achieve LTR with PRN therapy. Despite the above mentioned studies, the characteristics of the patients with LTR have not been previously evaluated in the literature. Therefore, we've conducted this study to evaluate the characteristics of the patients with wet AMD with LTR during as-needed therapy.
Methods
This was a retrospective review of eyes that were treated with as-needed anti-VEGF therapy for wet AMD at the Jacobs Retina Center, Shiley Eye Institute, University of California San Diego (UCSD) between 2009 and 2014. The study was conducted according to the Helsinki Declaration, and complied with the Health Insurance Portability and Accountability Act of 1996. Written informed consent was obtained for each patient before the anti-VEGF intravitreal therapy. University of California San Diego Institutional Review Board approval was acquired for the review and analysis of patients' data.
All AMD patients who developed LTR after anti-VEGF therapy were identified through a search of the database of imaging records at the Jacobs Retina Center and included in the analysis as the remission group. Long-term remission was defined as absence of IRF, SRF or hemorrhage on OCT for longer than 6 months, as well as no leakage on fluorescein angiography during this period. Age-and gender-matched patients with wet AMD treated with as-needed anti-VEGF therapy who did not achieve LTR were included as the control group. We compared the presentation features of patients with LTR with those in the control group.
All the patients were diagnosed with wet AMD and treated by a single experienced retinal specialist (W.R. F.) based on clinical characteristics and multimodal imaging including spectral domain-optical coherence tomography (SD-OCT) and fluorescein angiography at a single institution. The treatment regimen was as needed after an initial loading dose of 3 monthly injections, with monthly evaluation and reinjection until the eye became completely dry, after which we give one to two bonus injections before going to an observation phase. Treatment indications included presence of IRF or SRF on OCT, new or persistent hemorrhage on color fundus photography or ophthalmoscopy, decreased visual acuity as compared with the previous examination, or leakage on fluorescein angiography. Retinal pigment epithelial detachments were not an indication for treatment. Patients were treated with intravitreal 1.25 mg bevacizumab initially. In resistant cases, treatment was switched to aflibercept given every 8 weeks without any loading doses. 15 When there was persistent IRF or SRF despite a minimum of 5 injections given every 8 weeks, the interval between the injections of aflibercept was decreased to every 4 weeks. Intravitreal injection of therapeutics such as bevacizumab or aflibercept was carried out under aseptic conditions in the clinic. Preservative-free lidocaine gel 15 was instilled in the eye for at least 5 minutes prior to injection. A lid speculum was placed to keep the lids open and 5% povidone iodine solution was instilled on the conjunctival sac prior to injection. The intravitreal injection was performed using a 30-gauge needle in the superotemporal or superonasal quadrant, 3.5 mm to 4.0 mm posterior to the limbus depending on lens status.
Patients who underwent pars plana vitrectomy for severe subretinal hemorrhage due to wet AMD, advanced glaucoma, corneal pathology, and coexisting macular disease that may influence visual acuity were excluded. The same exclusion criteria were used for both groups.
The demographic characteristics at the time of presentation, including age, gender, and ethnicity, were collected at the initial visit. The type and number of injections of anti-VEGF agents (aflibercept or bevacizumab), and the duration of remission were recorded from the clinical chart. The number of patients achieving LTR at 1-, 2-, and 3-year-windows was noted. The visual acuity was measured using a standard Early Treatment Diabetic Retinopathy Study chart, and noted as the closest logarithm of the minimum angle of resolution line that the patient got three or more letters on.
The choroidal neovascular membrane (CNV) type, CNV size, central foveal thickness, presence of posterior vitreous detachment, presence and type of pigment epithelium detachment, and subfoveal choroidal thickness were assessed using SD-OCT (Spectralis HRA + OCT; Heidelberg Engineering, Carlsbad, CA) from horizontal or vertical scans passing through the central fovea, and measured using the calipers feature or thickness profile of the Spectralis device. Choroidal neovascularization was classified as Type 1 (sub-RPE), Type 2 (subretinal), and Type 3 (retinal angiomatous proliferation (RAP))-based on SD-OCT findings. The presence of macular atrophy and macular scar were also assessed by checking several SD-OCT scans cutting through the fovea. Macular atrophy was defined as loss of outer retinal layers and RPE with increased hyperreflectivity of the choroid within 500 mm in either direction of fovea in SD-OCT scan. Macular atrophy greater than 100 mm was considered for statistical analysis. All SD-OCT images starting from the presentation visit were reviewed, and the date when macular atrophy started to occur was noted.
Statistical analyses were conducted using SAS software version 9.4 (SAS Institutes, Cary, NC). Descriptive statistics included mean, SD, median, range, and percentages. The Shapiro-Wilk test was used to test normality of the data. Chi-square test or Fisher's exact test was used to compare categorical variables, and the test was used to compare continuous variables between groups. P values represent results for two-sided tests, with values less than 0.05 considered statistically significant. Kaplan-Meier curves were generated for the time for having LTR and time for having macular atrophy in all patients with wet AMD (232 eyes), and the log-Rank test was used to compare survival rates between the two groups.
Results
Among the 232 eyes (205 patients) with wet AMD treated at our institution, 27 eyes (11.6%) of 25 patients achieved LTR. The mean time from presentation to last treatment to achieve LTR was 19 months (range 3-52 months). The mean remission time was 18 months (range 6-44 months). Forty-one percent of eyes (11 eyes) achieved LTR during the first year of presentation; 26% of eyes (7 eyes) had LTR at 2 years; and 9 eyes (33.3%) had LTR at 3 years. There was no significant difference in the mean follow-up duration between the two groups (42 ± 18.4 months in LTR group vs. 40.05 ± 12.3 months in the control group, P = 0.2). Figure 1 shows the Kaplan-Meier curve for time to achieve LTR.
A group of age-, gender-, and ethnicity-matched patients with wet AMD (32 eyes of 28 patients) without LTR were selected as the control group. The mean age of these 53 patients was 79.3 ± 6.7 years old, and 33 (62.3%) of them were women. The demographic characteristics of the patients in both groups are summarized in Table 1 .
Compared with the control group, eyes with LTR had significantly thinner mean subfoveal choroidal thickness at baseline (147.1 vs. 177.7 mm, P = 0.04). There was significantly more IRF and less SRF at baseline in the LTR group (59.3% IRF, 11.1% SRF and 29.6% IRF + SRF) when compared with the control group (28.1% IRF, 34.4% SRF and 37.5% IRF + SRF, P = 0.03). Choroidal neovascular membranes were more often subfoveal in the remission group than in the control group (85.2% vs. 62.5%, P = 0.06). The mean central foveal thickness at baseline was thinner Fig. 1 . Kaplan-Meier curve of the survival time to achieve long-term remission in eyes with neovascular age-related macular degeneration treated with as needed anti-VEGF therapy.
in the remission group than in the control group (275 vs. 315 mm, P = 0.07). There was no significant difference between two groups in terms of baseline lens status (P = 0.61), presence of RPE detachment or not (P = 0.55), logarithm of the minimum angle of resolution visual acuity P = 0.55), and posterior vitreous status (detached or attached) (P = 1.00) between two groups. There was a significant difference in CNV type between the two groups (chi-square test, P = 0.036). In eyes achieving LTR , 74% of eyes (20 eyes) had Type 1 CNV, and RAP was the second most common CNV type with a rate of 18.5% (five eyes). In the control group, 28 eyes (87.5%) had Type 1 CNV, four eyes (12.5%) had Type 2, and none of the patients (0%) had RAP. The clinical characteristics at presentation in the eyes achieving LTR and control eyes are summarized in Table 2 .
There was a higher proportion of aflibercept usage in the control group compared with the remission group (96.9% vs. 48.1%, P , 0.001), as we switched treatment from bevacizumab to aflibercept in refractory cases. The mean central foveal thickness at the last visit was significantly thinner in the remission group compared with the control group (188 vs. 233 mm, P = 0.01). Similarly, the subfoveal choroidal thickness was thinner in the LTR group than in the control group (146 vs. 171 mm, P = 0.04) at the last visit. However, there was no significant difference in visual acuity and visual acuity change from baseline at the last visit between the two groups. The treatment modalities and the clinical statuses at the last visit are summarized for both groups in Table 3 .
Among 232 eyes with wet AMD, 83 eyes (35.7%) had macular atrophy during a mean of 31.6 ± 23.5 months follow-up. In the control group, 25% of eyes (8 eyes) had macular atrophy during the follow-up, and 66.6% of eyes (18 eyes) had macular atrophy in the LTR group. There was a significant difference in the incidence of macular atrophy (P = 0.001, chisquare test). The median estimated time for all eyes (n = 232) to develop macular atrophy was 66.7 ± 7 months (95% CI: 52-79.5 months). The median estimated time to develop macular atrophy in eyes achieving LTR (n = 27) was 45.7 ± 8.01 months (95% CI: 30-61), and was 56.5 ± 2.5 months (95% CI: 53-71) in eyes not achieving LTR (N = 205). There was a significant difference in the estimated time to develop macular atrophy between the LTR group (n = 27) and cohort patients (n = 205) (log Rank = 0.008). Figure 2 shows the time to develop macular atrophy in our cohort. 
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At last follow-up, 4 eyes (14.8%) in the LTR group had a macular scar, while 2 eyes (6.3%) had scar in the control group (P = 0.257).
Discussion
Treat-and-extend, and PRN regimens, are commonly used to treat wet AMD in clinical practice. In our PRN regimen with monthly evaluation, we found that thinner choroidal thickness, more IRF, less SRF, and the presence of RAP at baseline were associated with LTR. This has not been reported previously.
Since the choroid is mainly composed of vessels and capillaries, one may assume that choroidal thickness is a marker of the choroidal circulation, which provides oxygen and nourishment to the outer retinal layers and the RPE, maintaining the RPE and outer retinal integrity. 16 Previous studies have suggested that abnormalities of the choroidal circulation are involved in the development of AMD. [17] [18] In wet AMD, choroidal circulation might be essential to maintain the activity of CNV. A thinner choroid may represent a damaged choroidal circulation that does not have sufficient blood flow to maintain CNV activity, allowing for LTR with anti-VEGF treatment. A similar clinical phenomenon supporting this hypothesis is that in high myopia, CNV is associated with a thin choroid and usually regresses with fewer anti-VEGF injections compared with wet AMD. 19 We found that more IRF and less SRF at presentation were associated with LTR. Interestingly, SRF has been reported to be refractory to anti-VEGF treatments, and SRF itself has a minor impact on visual acuity prognosis when compared with IRF. [20] [21] [22] Patients with SRF might be refractory to both anti-VEGF and photodynamic therapy. 20 In a recent LogMAR, logarithm of the minimum angle of resolution. study, 23 SRF predicted a higher number of ranibizumab injections and a higher number of photodynamic therapy (PDT) treatments in the combination treatment group. However, patients with IRF presented with the lowest initial visual acuity, and IRF had a strong negative predictive value on visual improvement. 21, 22 In the CATT study, 10.7% of patients had RAP lesion at baseline. 24 At 1 year, eyes with RAP were more likely to have no fluid on OCT, no leakage on fluorescein angiography, and geographic atrophy at both 1 and 2 years. These eyes also required fewer anti-VEGF injections compared with eyes that did not have RAP lesions at 2 years (5.36 vs. 6.57, P = 0.018). The CATT study suggested that the increased geographic atrophy development may be related to baseline subfoveal choroidal thinning, reticular pseudodrusen, and atrophy in the fellow eye. 25 In this study, among 59 control and LTR eyes, 8.4% of patients had an RAP lesion at presentation, and the RAP lesion was related to achieving LTR. Unlike the CATT study, in which atrophy evaluated using fluorescein angiography and color fundus photography was reported to be 18.3% in this study, 44.1% of patients had some atrophy during the follow-up. Patients with macular atrophy were most likely to get LTR during the follow-up. The variation in the rate of macular atrophy may be explained by the difference in method used for the evaluation of macular atrophy. Although the characteristics of the patients with RAP lesion have been well elucidated in the literature, our study is the first one reporting the features of patients with LTR.
Achieving LTR may also be related with the anti-VEGF agent used. Although in VIEW trails, 6 ranibizumab dosed monthly was found to be noninferior to aflibercept injections. In our study, there was a higher proportion of aflibercept usage in the control group compared with the LTR group (96.9% vs. 48.1%), which may be explained by our practice of routinely switching from bevacizumab to aflibercept in refractory cases.
This study has several limitations, including its retrospective nature and relatively small study population. In our study, there is a significant proportion of patients who achieved LTR using PRN treatment. However, our results are limited to the PRN regimen and do not allow us to compare rates of LTR with a treat-and-extend regimen. Further studies are needed to address this issue. Although we used Kaplan-Meier analyses which take censoring into account, it would be interesting to study the characteristics of all patients presenting with wet AMD. On the other hand, since our institution is a referral center, it is highly likely that patients who present to our clinic may have more severe disease. However, only multicenter prospective clinical trials can address this issue by avoiding bias. A strength of the study is that it is the first study looking for the baseline features of patients with wet AMD achieving LTR while on as-needed anti-VEGF treatment. The same experienced retina specialist used an identical treatment algorithm for all patients. This study is also void of any bias from pharmaceutical sponsorship and compares remission with therapy with both aflibercept and bevacizumab, so the data is generalizable to the typical retina practice patient.
In conclusion, in patients with wet AMD treated with as-needed anti-VEGF therapy, a thinner choroidal thickness, presence of RAP, and more IRF and less SRF at baseline are associated with a higher likelihood of achieving LTR in a PRN treatment regimen. Patients who have macular atrophy during follow-up are most likely to get LTR.
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